Pure Global Cannabis, Inc. (OTC Pink: PRCNF) (TSXV: PURE) is a Canadian-based cannabis company. Shares surged 55.81% on Monday, January 14, 2019. Over the past month, Pure Global has seen an average daily volume of 78,288 shares. However, on Monday, 900,999 shares traded hands, equating to $198,200 in dollar volume.
Shares surged Monday after Pure Global announced on Friday, January 11, 2019 that its subsidiary, PureSinse, Inc., has secured the necessary licenses from Health Canada to begin selling cannabis in Canada. PureSinse will initially offer two dozen different premium cannabis products to medical patients through its e-commerce site. The obtained licenses also allows for the sale of cannabis to the adult recreational use market. PureSinse is currently “launching uniquely curated lines of consumer products tailored to specific market segments.” PureSinse is also involved in “one of the largest real-world evidence-based clinical studies,” testing the “therapeutic benefits of specific cannabis strains for commonly reported medical symptoms.” Malay Panchal, CEO of Pure Global, commented, “We feel the medical community has been hugely underserviced with poor patient and physician education, and product offerings, areas we hope to be trail blazers in and make a significant contribution to in 2019.” Here is the full press release detailing the licenses obtained by PureSinse:
Pure Global Cannabis, Inc. Press Release:
TORONTO, Jan. 11, 2019 /CNW/ – Pure Global Cannabis Inc. (TSX.V:PURE; OTC: PRCNF; FRA:1QS) (the “Company” or “Pure Global”) an integrated, growth-oriented life sciences and consumer products cannabis company, through its subsidiary PureSinse Inc. (“PureSinse”), is excited to announce that Health Canada has issued PureSinse a Sales License under the Cannabis Act.
Eligible and pre-registered Canadian medical patients can soon select from two dozen premium cannabis products offered by PureSinse, via its newly launched eCommerce website at PureSinse.com. The Company is committed to supporting medical cannabis patients by emphasizing the quality of and access to the products they need. The Company anticipates growing to 70 SKUs (stock-keeping units) by mid-2019, including adding extracted oil products, and vape pens.
PureSinse continues to demonstrate commitment to the medical community by leading one of the largest real-world evidence-based clinical studies in conjunction with the Appletree Medical Group and one of the largest Clinical Research Organizations in the world. The clinical data, which will be collected from thousands of patients, will provide necessary data points for guidance in the therapeutic benefits of specific cannabis strains for commonly reported medical symptoms. This evidence will guide PureSinse’s future pharmaceutical product and consumer product development plans and provide the medical community with published peer reviewed observational data on the efficacy of medical cannabis for a range of conditions.
As part of the Sales Licence, the Company can also sell products into the adult-legal consumer market through provincially licensed retailers, for which it is launching uniquely curated lines of consumer products tailored to specific market segments.
“This is a significant milestone for us and something we have been vigorously preparing for over the last several months,” said Malay Panchal, CEO of Pure Global. “We feel the medical community has been hugely underserviced with poor patient and physician education, and product offerings, areas we hope to be trail blazers in and make a significant contribution to in 2019,” added Mr. Panchal.
About Pure Global Cannabis
Pure Global Cannabis Inc. (TSX.V:PURE; OTC:PRCNF; FRA:1QS) is an innovation-based cannabis Company led by experienced pharma, biotechnology, horticultural, and consumer packaged goods (CPG) experts. The Company’s wholly owned subsidiary, PureSinse Inc., is a licensed producer under the Cannabis Act. The Company’s Brampton campus houses facilities for vertically farmed cultivation, R&D, extraction, manufacturing, and distribution. PURE will produce branded and white-labeled cannabis products for the medical, pharmaceutical, wellness, health & beauty, natural health, food & beverage, and recreational legal markets with uniquely formulated and purified concentrates. The Company is using the Canadian market as a springboard to develop and manufacture GMP-compliant cannabis products for international sale and distribution with a goal to become one of the most trusted premium international cannabis brands.
To register to Pure Global’s mailing list, please visit www.pureglobal.com. Follow @pureglobalcanna on Twitter and Facebook and @pureglobalcannabis on Instagram.
This news release contains certain forward-looking statements, including, but not limited to, statements about Pure Global’s future plans and intentions. Wherever possible, words such as “may”, “will”, “should”, “could”, “expect”, “plan”, “intend”, “anticipate”, “believe”, “estimate”, “predict” or “potential” or the negative or other variations of these words, or similar words or phrases, have been used to identify these forward-looking statements. These statements reflect management’s current beliefs and are based on information currently available to management as at the date hereof.
Forward-looking statements involve significant risk, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from the results discussed or implied in the forward-looking statements. These factors should be considered carefully and readers should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this news release are based upon what management believes to be reasonable assumptions, Pure Global cannot assure readers that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this news release, and Pure Global assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law.
Article By: Andrew Rego